000			03602 a2200229 4500
999			_c35938 _d35938
001			nam a22 7a 4500
020			_a9781509868087
082			_a338.7​681761 CA BA
100			_aCarreyrou, John _927877
245			_aBad blood : _bsecrets and lies in a Silicon valley startup / _cJohn Carreyrou
260			_aLondon : _bPicador, _c2019.
300			_axii, 339 p. ; _c20 cm.
520			_aA New York Times Bestseller Longlisted for the Financial Times and McKinsey Business Book of the Year Award 'Chilling ... Reads like a West Coast version of All the President's Men.' New York Times Book Review The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley. Now to be adapted into a film, with Jennifer Lawrence to star. The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
650			_aHolmes, Elizabeth, 1984- _928016
650			_aSecurities fraud _vUnited States _xCase studies _928017
650			_aFraud _vUnited States _xCase studies _951337
650			_aNew business enterprises _xCorrupt practices _vUnited States _zCase studies _928019
650			_aHematologic equipment industry _vUnited States _927879
650			_aFraud _vUnited States _xCase studies _951338
856			_uhttps://uowd.box.com/s/voi1l0hzdxefb6h2nsi3g137q5lpq5h8 _zLocation Map
942			_cREGULAR